Health Catalyst (NASDAQ:HCAT) Rating Reiterated by Canaccord Genuity Group

Health Catalyst (NASDAQ:HCAT)‘s stock had its “buy” rating reiterated by equities researchers at Canaccord Genuity Group in a report issued on Tuesday, Benzinga reports. They currently have a $11.00 target price on the stock. Canaccord Genuity Group’s price target would indicate a potential upside of 60.58% from the company’s current price.

HCAT has been the topic of several other research reports. Piper Sandler reiterated an “overweight” rating and issued a $15.00 price objective (down previously from $17.00) on shares of Health Catalyst in a research note on Friday, February 23rd. Cantor Fitzgerald reiterated an “overweight” rating and set a $16.00 price objective on shares of Health Catalyst in a report on Wednesday, April 10th. Guggenheim upgraded Health Catalyst from a “neutral” rating to a “buy” rating and set a $14.00 target price on the stock in a research note on Friday, January 26th. Wells Fargo & Company cut their price target on Health Catalyst from $14.00 to $13.00 and set an “overweight” rating for the company in a research note on Friday, May 10th. Finally, Evercore ISI lowered their price target on Health Catalyst from $11.00 to $10.00 and set an “outperform” rating for the company in a research note on Friday, February 23rd. Three research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $12.18.

Health Catalyst Stock Up 1.2 %

HCAT opened at $6.85 on Tuesday. The firm has a market capitalization of $404.36 million, a P/E ratio of -3.70 and a beta of 1.32. The stock has a fifty day moving average of $6.72 and a 200-day moving average of $8.11. Health Catalyst has a 12-month low of $5.45 and a 12-month high of $14.37.

Health Catalyst (NASDAQ:HCAT) last announced its quarterly earnings data on Thursday, February 22nd. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.06. Health Catalyst had a negative return on equity of 11.86% and a negative net margin of 35.56%. The firm had revenue of $75.08 million during the quarter, compared to the consensus estimate of $73.67 million. On average, analysts expect that Health Catalyst will post -0.47 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of HCAT. Bank of New York Mellon Corp grew its position in shares of Health Catalyst by 124.0% in the third quarter. Bank of New York Mellon Corp now owns 854,896 shares of the company’s stock valued at $8,652,000 after purchasing an additional 473,323 shares during the last quarter. Principal Financial Group Inc. increased its position in Health Catalyst by 38.4% in the 3rd quarter. Principal Financial Group Inc. now owns 25,793 shares of the company’s stock worth $261,000 after buying an additional 7,152 shares during the period. Versor Investments LP acquired a new position in shares of Health Catalyst during the third quarter worth approximately $117,000. Fox Run Management L.L.C. acquired a new position in Health Catalyst during the 3rd quarter valued at $166,000. Finally, Barclays PLC boosted its holdings in Health Catalyst by 135.1% in the 3rd quarter. Barclays PLC now owns 53,209 shares of the company’s stock valued at $538,000 after purchasing an additional 30,580 shares during the period. 85.00% of the stock is currently owned by institutional investors and hedge funds.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.